ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+158.1% YoY

Gross Profit

$19M100.0% margin

Operating Income

-$107M-561.8% margin

Net Income

-$107M-565.9% margin

EPS (Diluted)

$-1.25

QoQ Revenue Growth

+8.6%

Cash Flow

Operating Cash Flow

-$100M

Free Cash Flow

-$136M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$303M

Stockholders' Equity

$831M

Cash & Equivalents

$171M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$7M	+158.1%
Gross Profit	$19M	$7M	+158.1%
Operating Income	-$107M	-$110M	+3.2%
Net Income	-$107M	-$103M	-4.2%

ALNY Q1 2017 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena